You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Programmed Cell Death 1 Receptor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)

Recruiting
  • Relapsed Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Nivolumab
  • Pembrolizumab
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Jul 22, 2022

Cancer Trial in United States (JTX-4014)

Active, not recruiting
  • Cancer
  • Denver, Colorado
  • +3 more
Sep 9, 2022

Non Small Cell Lung Cancer, Solid Tumor Trial in Fairfax (BBP-398 with nivolumab)

Recruiting
  • Non Small Cell Lung Cancer
  • Solid Tumor
  • BBP-398 with nivolumab
  • Springdale, Arkansas
  • +6 more
Jan 27, 2023

Cervical Cancer, Chemo Effect, Programmed Cell Death 1 Receptor / Antagonists & Inhibitors Trial (Sindilimab +paclitaxel+

Not yet recruiting
  • Cervical Cancer
  • +3 more
  • Sindilimab +paclitaxel+ cisplantin
  • (no location specified)
Mar 14, 2021

Cervical Carcinoma, Chemoradiotherapy, Anti-programmed Cell Death Receptor 1 Trial in Beijing (Camrelizumab plus Concurrent

Recruiting
  • Cervical Carcinoma
  • +8 more
  • Camrelizumab plus Concurrent chemoradiotherapy
  • Beijing, Beijing, China
    Lei Li
Apr 5, 2022

Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma, Persistent Cervical Carcinoma Trial in Beijing (Tislelizumab plus

Recruiting
  • Recurrent Cervical Carcinoma
  • +9 more
  • Tislelizumab plus radiotherapy
  • Beijing, Beijing, China
    Lei Li
Apr 1, 2022

Relapsed/ Refractory Multiple Myeloma Trial in Worldwide (Talquetamab, Teclistamab, PD-1 Inhibitor)

Recruiting
  • Relapsed/ Refractory Multiple Myeloma
  • Denver, Colorado
  • +19 more
Jan 27, 2023

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Tumor Trial in

Suspended
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
May 23, 2022

NSCLC (NSCLC) Trial in Shanghai (Tumor treating fields(EFE-P100), Docetaxel injection)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Tumor treating fields（EFE-P100）
  • Docetaxel injection
  • Shanghai, China
    Shanghai Pulmonary Hospital
Dec 21, 2022

NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Wuhan, Hubei, China
    Qian Chu
Aug 18, 2023

NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +4 more
  • MK-2870
  • +2 more
  • (no location specified)
Sep 15, 2023

Acute Lymphoblastic Leukemia in Pediatric Trial in Sohag (flow cytometric immunophynotyping)

Not yet recruiting
  • Acute Lymphoblastic Leukemia in Pediatric
  • flow cytometric immunophynotyping
  • Sohag, Egypt
    Sohag University Hospital
Jun 19, 2022

Tumor-Infiltrating Lymphocytes and Programmed Cell Death -

Recruiting
  • Breast Cancer
  • +2 more
  • Observational Study
  • Lucknow, Uttar Pradesh, India
    Sanjay Gandhi Postgraduate Institute of Medical Sciences
Feb 11, 2022

Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Peking, China
    Peking Union Medical College Hospital
Nov 16, 2023

Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in

Recruiting
  • Malignant Pleural Mesothelioma, Advanced
  • Oncolytic Adenovirus H101
  • Programmed death receptor-1 inhibitor
  • Tianjin, Tianjin, China
    Tianjin Medical Unversity Second Hospital
Sep 2, 2023

Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Chuo-ku, Tokyo, Japan
    National Cancer Center Hospital ( Site 3700)
Jan 31, 2023

PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC

Recruiting
  • Non-small Cell Lung Cancer
  • Monza, Italy
    ASST-Monza Ospedale San Gerardo
Jun 9, 2022

Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor Trial in Chengdu (lenvatinib

Enrolling by invitation
  • Hepatocellular Carcinoma Non-resectable
  • +3 more
  • lenvatinib + sindilimab/carrelizumab
  • TACE
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
May 23, 2022

Hepatitis B, Chronic Trial in Worldwide (JNJ-73763989, PD-1 inhibitor, Tenofovir Disoproxil)

Recruiting
  • Hepatitis B, Chronic
  • Vancouver, British Columbia, Canada
  • +31 more
Jan 17, 2023

Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell

Recruiting
  • Primary Immune Deficiency
    • Bethesda, Maryland
    • +6 more
    Feb 2, 2023

    Soluble Programmed Death-1 in Predicting Progression of

    Recruiting
    • Nontuberculous Mycobacterial Lung Disease
      • Taipei, Taiwan
        National Taiwan University Hospital
      Jan 18, 2023

      Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,

      Not yet recruiting
      • Muscle-Invasive Bladder Carcinoma
      • +2 more
      • Guangzhou, Guangdong, China
        Cancer Center, Sun Yat-sen University
      Aug 3, 2023

      Programmed Death Ligand-1 in Nasopharyngeal and Hyypopharyngeal

      Not yet recruiting
      • Nasopharyngeal and Hypopharyngeal Carcinoma
      • immunohistochemical
      • Sohag, Egypt
        Sohag University Hospital
      Oct 23, 2022

      Metastatic Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer Trial in Philadelphia (Stereotactic Body Radiotherapy)

      Active, not recruiting
      • Metastatic Nonsmall Cell Lung Cancer
      • Non Small Cell Lung Cancer
      • Stereotactic Body Radiotherapy
      • Philadelphia, Pennsylvania
        Philadelphia CyberKnife
      Mar 15, 2022

      Locally Advanced Cervical Cancer Trial in Villejuif (Atezolizumab, Radiotherapy, Cisplatin)

      Recruiting
      • Locally Advanced Cervical Cancer
      • Villejuif, Val De Marne, France
        Gustave Roussy
      Feb 15, 2022